Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells

Cancer Science

Volumn 102, Issue 3, 2011, Pages 591-596

  Takeuchi, Miki ^a,b   Ashihara, Eishi ^a,c   Yamazaki, Yohko ^d   Kimura, Shinya ^e   Nakagawa, Yoko ^a   Tanaka, Ruriko ^a   Yao, Hisayuki ^a   Nagao, Rina ^a   Hayashi, Yoshihiro ^a,b   Hirai, Hideyo ^a   Maekawa, Taira ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d INSTITUTE OF MICROBIAL CHEMISTRY   (Japan)

^e SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; DASATINIB; IMATINIB; RAKICIDIN A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL HYPOXIA; CELL STRUCTURE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; IC 50; LEUKEMIA; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL;

ADAPTATION, PHYSIOLOGICAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL HYPOXIA; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIPOPEPTIDES; NEOPLASTIC STEM CELLS; PEPTIDES, CYCLIC; PROTEIN KINASE INHIBITORS;

EID: 79951713930     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01813.x     Document Type: Article

References (40)

1. Vaupel P, Kelleher DK, Hockel M. Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001; 28: 29-35.
2. Kizaka-Kondoh S, Inoue M, Harada H et al. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 2003; 94: 1021-8.
3. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-9.
4. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 6: 437-47.
5. Hockel M, Schlenger K, Aral B et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-15.
6. Parmar K, Mauch P, Vergilio JA et al. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007; 104: 5431-6.
7. Cipolleschi MG, Dello Sbarba P, Olivotto M. The role of hypoxia in the maintenance of hematopoietic stem cells. Blood 1993; 82: 2031-7.
8. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-40.
9. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-64.
10. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17.
11. Michor F, Hughes TP, Iwasa Y et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267-70.
12. Copland M, Hamilton A, Elrick LJ et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-9.
13. + leukemic cells acquiring stem-like characteristics in hypoxic environment. Cell Death Differ 2010; 17: 1211-20.
14. Yamazaki Y, Kunimoto S, Ikeda D. Rakicidin A: a hypoxia-selective cytotoxin. Biol Pharm Bull 2007; 30: 261-5.
15. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talay method. Cancer Res 2010; 70: 440-6.
16. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-81.
17. Kimura S, Kuroda J, Segawa H et al. Antiproliferative efficacy of the third generation bisphosphate zoledronic acid combined with other anticancer drugs in leukemic cell lines. Int J Hematol 2004; 79: 37-43.
18. Kamitsuji Y, Kuroda J, Kimura S et al. Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ 2008; 15: 1712-22.
19. Kimura S, Maekawa T, Hirakawa K et al. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 1995; 55: 1379-84.
20. Okada M, Adachi S, Imai T et al. A novel mechanism for imatinib mesylate- induced cell death of BCR-ABL-positive human leukemic cells: caspase- independent, necrosis-like programmed cell death mediated by serine protease activity. Blood 2004; 103: 2299-307.
21. Kawata E, Asihara E, Nakagawa Y et al. A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid supresses the growth of malignant methothelioma cells in vitro. Cancer Lett 2010; 294: 245-53.
22. Tanaka R, Kimura S. From the second generation Abl tyrosine kinase inhibitors to the next generation for overriding Bcr-Abl/T315I. Expert Rev Anticancer Ther 2008; 8: 1387-98.
23. Graham SM, Jørgensen HG, Allan E. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-25.
24. Ishikawa F, Yoshida S, Saito Y et al. Chemotherapy-resistant human AML stem cells home to engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315-21.
25. Jensen PØ, Mortensen BT, Hodgkiss RJ et al. Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats. Cell Prolif 2000; 33: 381-95.
26. Giuntoli S, Rovida E, Barbetti V. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations. Leukemia 2006; 20: 1291-3.
27. Giuntoli S, Rovida E, Gozzini A. Severe hypoxia defines heterogeneity and selects highly immature progenitors within clonal erythroleukemia cells. Stem Cells 2007; 25: 1119-25.
28. Ninomiya M, Abe A, Katsumi A et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 2007; 21: 136-42.
29. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321-31.
30. Desplat V, Faucher JL, Mahon FX et al. Hypoxia modifies proliferation and differentiation of CD34(+) CML cells. Stem Cells 2002; 20: 347-54.
31. Sasai K, Yajima H, Suzuki F. Suppression of postmitochondrial signaling and delayed response to UV-induced nuclear apoptosis in HeLa cells. Jpn J Cancer Res 2002; 93: 275-83.
32. Cande C, Cohen I, Daugas E et al. Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie 2002; 84: 215-22.
33. Liu L, Xing D, Chen WR. Micro-calpain regulates caspase-dependent and apoptosis inducing factor-mediated caspase-independent apoptotic pathways in cisplatin- induced apoptosis. Int J Cancer 2009; 12: 2757-66.
34. Zeman EM, Brown JM, Lemmon MJ et al. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986; 12: 1239-42.
35. Brown JM. The hypoxic cell: a target for selective cancer therapy. Cancer Res 1999; 59: 5863-70.
36. Shibata T, Shibamoto Y, Sasai K et al. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation. Jpn J Cancer Res 1996; 87: 98-104.
37. Masunaga S, Ono K, Suzuki M et al. Usefulness of tirapazamine as a combined agent in chemoradiation and thermo-chemoradiation therapy at mild temperatures: reference to the effect on intratumor quiescent cells. Jpn J Cancer Res 2000; 91: 566-72.
38. Liu F, Wang P, Jiang X et al. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 2008; 99: 2055-61.
39. Doroshow JH. Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinines. Proc Natl Acad Sci U S A 1986; 83: 4514-18.
40. Shinha BK, Mimnaugh EG. Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radic Biol Med 1990; 8: 567-81.